Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation

European Journal of Clinical Investigation

Volumn 38, Issue 12, 2008, Pages 945-952

  Boehm, A ^a   Sperr, W R ^a   Leitner, G ^a   Worel, N ^a   Oehler, L ^a   Jaeger, E ^a   Mitterbauer, M ^a   Haas, O A ^b   Valent, P ^a   Kalhs, P ^a   Rabitsch, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Allogeneic stem cell transplantation; Comorbidity; MDS; Secondary AML

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; COMORBIDITY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AUSTRIA; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RECURRENCE; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 56649112687     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.02041.x     Document Type: Article

References (45)

1. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007 31 : 727 36.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982 51 : 189 99.
3. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW et al. Myelodysplastic syndromes. In : Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon : France IARC Press 2001 62 73.
4. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004 104 : 579 85.
5. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985 59 : 425 33.
6. Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998 21 : 255 61.
7. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB et al. Therapy-related leukaemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986 4 : 1748 57.
8. Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000 95 : 1188 94.
9. Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998 92 : 1910 7.
10. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998 12 (Suppl 1 S25 9.
11. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000 110 : 620 30.
12. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006 20 : 128 35.
13. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006 20 : 322 8.
14. Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002 119 : 144 54.
15. Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002 100 : 1997 2004.
16. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 89 : 2079 88.
17. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Ritz J et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008 14 : 28 35.
18. Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Société Française de Greffe de Moelle. Blood 1996 88 : 358 65.
19. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007 25 : 3503 10.
20. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005 23 : 7594 603.
21. Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F et al. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008 112 : 895 902.
22. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukaemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007 25 : 4246 54.
23. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005 106 : 2912 9.
24. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006 12 : 954 64.
25. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006 144 : 407 14.
26. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994 47 : 1245 51.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987 40 : 373 83.
28. Hansen JA, Mickelson EM, Choo SY et al. Clinical bone marrow transplantation: donor selection and recipient monitoring. In : Rose NR, de Macario EC, Fahey JL, Friedman H, Penn GM, editors. Manual of Clinical Laboratory Immunology. 4th ed. Washington, D.C. : American Society for Microbiology 1992 850 66.
29. Fischer GF, Faé I, Petrasek M, Moser S. A combination of two distinct in vitro amplification procedures for DNA typing of HLA-DRB and - DQB 1 alleles. Vox Sang 1995 69 : 328 35.
30. Winston DJ, Gale RP. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplant 1991 8 : 7 11.
31. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005 23 : 5675 87.
32. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986 314 : 729 35.
33. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001 97 : 3390 400.
34. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation. N Engl J Med 1975 292 : 832 902.
35. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981 57 : 267 76.
36. ISCN. An international system for human cytogenetic nomenclature. Cytogenet Cell Genet 1981 31 : 5 23.
37. Oehler L, Foedinger M, Koeller M, Kollars M, Reiter E, Bohle B et al. Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release. Blood 1997 89 : 1147 53.
38. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2008 45 : 49 59.
39. Ooi J. The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma 2006 47 : 599 602.
40. Ooi J, Iseki T, Takahashi S, Tomonari A, Ishii K, Takasugi K et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003 101 : 4711 3.
41. Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005 11 : 65 73.
42. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007 109 : 4586 8.
43. Partanen S, Juvonen E, Ruutu T. In vitro culture of haematopoietic progenitors in myelodysplastic syndromes. Scand J Haematol 1986 45 : 98 101.
44. Ruutu T, Partanen S, Lintula R, Teerenhovi L, Knuutila S. Erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Scand J Haematol 1984 32 : 395 402.
45. Bitan M, Or R, Shapira MY, Resnick IB, Gesundheit B, Ackerstein A et al. Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia. Bone Marrow Transplant 2008 41 : 69 78.